These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18657338)

  • 1. Selective pulmonary artery perfusion followed by blood flow occlusion: new challenge for the treatment of pulmonary malignancies.
    Grootenboers MJ; Schramel FM; van Boven WJ; Hendriks JM; van Schil PE; De Wit PE; Pasterkamp G; Folkerts G; van Putte BP
    Lung Cancer; 2009 Mar; 63(3):400-4. PubMed ID: 18657338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of gemcitabine when delivered by selective pulmonary artery perfusion for the treatment of lung cancer.
    van Putte BP; Grootenboers M; van Boven WJ; Hendriks JM; van Schil PE; Guetens G; De Boeck G; Pasterkamp G; Schramel F; Folkerts G
    Drug Metab Dispos; 2008 Apr; 36(4):676-81. PubMed ID: 18187564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective pulmonary artery perfusion for the treatment of primary lung cancer: Improved drug exposure of the lung.
    van Putte BP; Grootenboers M; van Boven WJ; van Oosterhout M; Pasterkamp G; Folkerts G; Schramel F
    Lung Cancer; 2009 Aug; 65(2):208-13. PubMed ID: 19097670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics after pulmonary artery perfusion with gemcitabine.
    Van Putte BP; Hendriks JM; Romijn S; Pauwels B; De Boeck G; Guetens G; De Bruijn E; Van Schil PE
    Ann Thorac Surg; 2003 Oct; 76(4):1036-40; discussion 1040. PubMed ID: 14529980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytostatic lung perfusion by use of an endovascular blood flow occlusion technique.
    Furrer M; Lardinois D; Thormann W; Altermatt HJ; Betticher D; Triller J; Mettler D; Althaus U; Burt ME; Ris HB
    Ann Thorac Surg; 1998 Jun; 65(6):1523-8. PubMed ID: 9647052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective pulmonary artery perfusion with melphalan is equal to isolated lung perfusion but superior to intravenous melphalan for the treatment of sarcoma lung metastases in a rodent model.
    Den Hengst WA; Hendriks JM; Van Hoof T; Heytens K; Guetens G; de Boeck G; Lardon F; Van Schil PE
    Eur J Cardiothorac Surg; 2012 Aug; 42(2):341-7; discussion 347. PubMed ID: 22345285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
    Kuemmerle A; Decosterd LA; Buclin T; Liénard D; Stupp R; Chassot PG; Mosimann F; Lejeune F
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):331-41. PubMed ID: 18587581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and efficacy of isolated lung perfusion with gemcitabine in a rat model of pulmonary metastases.
    Van Putte BP; Hendriks JM; Romijn S; De Greef K; Van Schil PE
    Thorac Cardiovasc Surg; 2006 Mar; 54(2):129-33. PubMed ID: 16541356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
    Van Putte BP; Hendriks JM; Romijn S; Pauwels B; Vermorken JB; Van Schil PE
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):125-30. PubMed ID: 15999051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs.
    Pagès PB; Derangere V; Bouchot O; Magnin G; Charon-Barra C; Lokiec F; Ghiringhelli F; Bernard A
    Eur J Cardiothorac Surg; 2015 Aug; 48(2):228-35. PubMed ID: 25414426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study.
    Beane JD; Griffin KF; Levy EB; Pandalai P; Wood B; Abi-Jaoudeh N; Beresnev T; Shutack Y; Webb CC; Avital I; Rudloff U
    Invest New Drugs; 2015 Feb; 33(1):109-18. PubMed ID: 25236592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion.
    van Riel JM; Peters GJ; Mammatas LH; Honeywell RJ; Laan AC; Ruyter R; van den Berg FG; Giaccone G; van Groeningen CJ
    Eur J Cancer; 2009 Sep; 45(14):2519-27. PubMed ID: 19556122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.
    Tse AN; Wu N; Patel D; Haviland D; Kemeny N
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):935-44. PubMed ID: 19221752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective pulmonary artery perfusion: a novel method for the treatment of pulmonary malignancies.
    Grootenboers MJ; Schramel FM; Hendriks JM; Van Boven WJ; Van Schil PE; Van Putte BP
    Acta Chir Belg; 2007; 107(4):361-7. PubMed ID: 17966526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine.
    Tanaka T; Sho M; Nishiofuku H; Sakaguchi H; Inaba Y; Nakajima Y; Kichikawa K
    AJR Am J Roentgenol; 2012 Jun; 198(6):1445-52. PubMed ID: 22623561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
    Shamseddine AI; Khalifeh MJ; Mourad FH; Chehal AA; Al-Kutoubi A; Abbas J; Habbal MZ; Malaeb LA; Bikhazi AB
    Clin Pharmacokinet; 2005; 44(9):957-67. PubMed ID: 16122282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified approach of administering cytostatics to the lung: more efficient isolated lung perfusion.
    van Putte BP; Hendriks JM; Guetens G; de Boeck G; de Bruijn EA; van Schil PE; Folkerts G
    Ann Thorac Surg; 2006 Sep; 82(3):1033-7. PubMed ID: 16928530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus radiotherapy for non-small cell lung cancer.
    Gregor A
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-39-S8-41. PubMed ID: 9207316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
    Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated lung perfusion with gemcitabine combined with radiotherapy: no additional lung toxicity in an experimental model.
    Van Thielen J; Wittock A; Hendriks J; den Hengst W; De Pooter C; Van den Weyngaert D; Pauwels P; Van Schil P
    Eur J Cardiothorac Surg; 2012 Oct; 42(4):712-8. PubMed ID: 22345281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.